Viedoc Technologies has recently published a white paper on how to be prepared for inspection when working in Viedoc.
Regulatory authorities expect to be able to review relevant documentation about the chosen systems used in a clinical trial. This expectation puts pressure on the sponsors and their representatives (CROs) to present the proper documentation upon inspection. But what is relevant? What should the sponsor or their representative have on hand and what can they expect the system supplier to deliver?
The white paper explains how Viedoc addresses inspector expectations on computerized systems used in clinical research. The paper details how Viedoc complies with clinical regulations, and how best to help you prepare for inspection by regulatory authorities.
The Viedoc Inspection Readiness Packet gives you access to all the necessary information you are expected to know about Viedoc and also advises on what additional documents you should have on hand if you should be inspected.
The white paper covers all of this, and much more, including:
Inspection Readiness
EMA CGP IWG Inspector Expectations
FDA Expectations
PDMA Expectations
Viedoc Inspection Readiness Packet
Sourcing a system for your trial
Available documentation
Documents you produce
Additional documents kept by you
Validations to perform
Pitfalls to be avoided
Get ready to be prepared — read the white paper now to learn more.
Announcement of Employment
UPPSALA / 2020-04-01
Viedoc Technologies is happy to announce the onboarding of Axel Stael von Holstein as Vice President of Business Development as of March 30th, 2020.
Axel comes to us with a long and varied experience within sales in the Life Science industry. His background gives him an extensive understanding of the market and our customers' needs.
Axel will be heading our Business Development department for the European market. His focus is to strengthen client relations and expand our customer base.
Filling the position of VP Business Development will ensure Viedoc's continued strong growth in Europe and around the world.
The Business Development team and entire Viedoc staff welcome Axel onboard.
Viedoc offers free licenses to support the global race for a COVID-19 vaccine
NEVER BEFORE HAS TIME BEEN MORE OF THE ESSENCE. We encourage every company in our field to join us in supporting the global research community in this effort. To do our part, Viedoc Technologies is offering free access to our software in all 2020 COVID-19 trials. Simply because it is the right thing to do.
Viedoc was created to help life science companies bring therapies to market faster by developing more efficient EDC technology. At no time has the impact of this mission been more evident than with the recent outbreak of the novel coronavirus (Covid-19). Only recently it would have been unthinkable to produce a completely new vaccine within the time frames that are being suggested today.
The outbreak of this virus has been responsible for the deaths of thousands globally and infected many more in a short period of time. The World Health Organization recently declared this to be a pandemic, only the fifth outbreak of this magnitude in over 120 years. Many measures are being taken by governments around the world to slow the extent of this novel virus. These steps taken are essential in slowing the spread to give the global scientific community time to find a vaccine.
We at Viedoc Technologies understand the importance and urgency of this unprecedented situation. This is why we are offering Viedoc free of charge to any institution in the search for a Covid-19 vaccine for the remainder of 2020.
For additional information, please contact us at Enable JavaScript to view protected content., and find out how we can get your study up and running in no time. Together, we can get a vaccine to market as soon as possible. In a world where minutes matter, we believe eClinical software can make a difference, one study at a time.
Responding to COVID-19 Viedoc continues fully operational
Viedoc has always been aware of how vital data safety, security, and access are to our customers. No matter the circumstances, we are committed to maintaining the high level of service expected of our clients.
Viedoc Technologies has been a stable provider of eClinical solutions for close to two decades now. We have always placed data integrity and security as our highest priority. The stability of our system has, in part, led to Viedoc's success and made us the dependable vendor we are today. Viedoc has always prioritized the security of data making us one of the most reliable players on the global market.
Just as important as the systems that run Viedoc are the people behind Viedoc. Our management team is continually monitoring the events surrounding the spread of the Covid-19 virus. The team's priorities are to ensure the safety of our staff and their families. And in doing so, assure the delivery of high-quality service to all our clients.
FAQ
Is Viedoc prepared?
Yes. We have implemented our long-established business continuity plan in case of an event of this magnitude to ensure safe and smooth operations moving forward, including that of our suppliers. With offices around the world, we have executed a work-from-home strategy to mitigate any possible infection of our team to keep them healthy and secure.
Have actions have been taken?
A risk management group has been formed to monitor the progress of the current crisis and some precautionary messures have been take to minimize risks. For example most of your employees are woking home based to ensure as few as possible get sick at the same time. We have also been in touch with all of our suppliers to ensure continued service.
Will access to my trial data be affected due to the outbreak?
No. We see no risk for service interruptions at this time. Viedoc is hosted in Microsoft Azure data centers in several locations around the world with robust redundancies and frequent backups allowing us to stand by our Service Level Agreements.
Is my data safe?
Absolutely. Our technicians monitor the well-being of the system every minute of every day, year-round. With data centers spread over the world, our shared resources give our platform robust endurance being able to share resources to even any load.
Will everyone in my study continue to have access?
Yes. Being a web-based solution gives all users the flexibility of working from wherever there is internet access. Remote monitoring during the Corona outbreak has become necessary for many, which is done simply and efficiently with Viedoc.
How stable is Viedoc Technologies, the company behind Viedoc?
Viedoc Technologies is a new name for many. However, we have been in this industry for nearly two decades. We have a broad and fantastic clientele spread over the globe. Our global presence is a strength allowing us to share duties and lighten the load whenever and wherever needed. All of this enables us to uphold a sound, safe, and robust system to the tens of thousands who use Viedoc every day.
For information about this or for any other questions you may have on data security and system quality, please reach out to us at Enable JavaScript to view protected content..
Announcement of promotion
Yusuke Nakazawa takes the position of General Manager at the Japanese offices on the 1st of March 2020
Nakazawa-san joined Pharma Consulting Group Japan KK in 2012 and since then has proved to be an invaluable member of the company. Beginning as a Technical Data Manager and working closely with all our Japanese clients, he has developed a fundamental understanding of the customers’ needs. Over the years he has held several positions within the company. Yet, customer needs have always been the primary focus for Nakazawa-san.
His promotion to the position of General Manager will ensure that PCG Japan and Viedoc will maintain their focus on the client. He will also secure continued growth and stability in the Asian markets.
Viedoc 4.33 版在ViedocMe模块中添加了视觉模拟量表(VAS)，受试人可通过VAS表选择痛感或疾病的强弱程度。 用户使用 iPad mini 2到iPad mini 4打开ViedocMe时，VAS量表显示长度为10cm。系统保存受试人录入信息的同时，所使用的的平板电脑型号也会一并记录。
